Canaccord analyst Edward Nash lowered the firm’s price target on Morphic to $66 from $68 and keeps a Buy rating on the shares. The firm said they updated their estimated potential FDA approval and commercial launch time frame of MORF-057 in UC from 2027 to 2029, as well as a one-year pushback in the launch for UC in the EU.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MORF: